Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer


Wu Y. , Tsuboi M., He J., John T., Grohe C., Majem M., ...More

NEW ENGLAND JOURNAL OF MEDICINE, vol.383, no.18, pp.1711-1723, 2020 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 383 Issue: 18
  • Publication Date: 2020
  • Doi Number: 10.1056/nejmoa2027071
  • Title of Journal : NEW ENGLAND JOURNAL OF MEDICINE
  • Page Numbers: pp.1711-1723

Abstract

BackgroundOsimertinib is standard-of-care therapy for previously untreated epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC). The efficacy and safety of osimertinib as adjuvant therapy are unknown.